Clinical Trial Update: Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating Fx-1006a in patients with ATTR-CM (TTR-CM) has completed, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Fx-1006A

Snippet

Sponsor: Pfizer | Conditions: ATTR-CM, TTR-CM | Phase 3 | Status: COMPLETED | Results posted: 2021-01-05